title: Tumor therapy with bispecific antibody: the targeting and triggering steps can be separated employing a CD2-based strategy.
abstract: For tumor therapy with unprimed effector cells, we developed a novel combination of a CD2 x tumor Ag bispecific targeting Ab and an anti-CD2 triggering Ab. These Ab constructs were derived from two novel CD2 mAbs, termed M1 and M2 that, together, but not individually activate T cells. Unlike many other CD2 Abs, M1 and M2 do not interfere with TCR/CD3 triggering nor do they inhibit binding of CD2 to its ligand CD58, thus preserving the physiological functions of these important effector cell molecules. M2 was chemically conjugated with an Ab recognizing the epidermal growth factor-receptor (EGF-R). Incubation of unprimed peripheral blood mononuclear cells with the bispecific F(ab')2 construct (M2xEGF-R) in the presence of trigger Ab M1 led to efficient selective lysis of EGF-R-positive targets by CTL and NK cells. Importantly, the need for trigger Ab M1 for effector cell stimulation allowed to separate targeting from triggering steps in vitro and should thus enable to focus immune responses to sites of target Ag expression in vivo.
authors.affiliation: Institute for Immunology, Ruprecht-Karls-Universitaet, Heidelberg, Germany.
authors.forename: M K
authors.initials: MK
authors.lastname: Wild
authors.forename: W
authors.initials: W
authors.lastname: Strittmatter
authors.forename: S
authors.initials: S
authors.lastname: Matzku
authors.forename: B
authors.initials: B
authors.lastname: Schraven
authors.forename: S C
authors.initials: SC
authors.lastname: Meuer
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000096:biosynthesis / Q000737:chemistry / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001665:Binding Sites / Q000276:immunology; D018801:CD2 Antigens / Q000276:immunology* / Q000378:metabolism; D002478:Cells, Cultured; D002999:Clone Cells; D018920:Coculture Techniques; D003601:Cytotoxicity Tests, Immunologic / Q000379:methods*; D066246:ErbB Receptors / Q000737:chemistry / Q000276:immunology / Q000502:physiology; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D018796:Immunoconjugates / Q000737:chemistry / Q000494:pharmacology; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018801:CD2 Antigens; D018796:Immunoconjugates; D007140:Immunoglobulin Fab Fragments; D066246:ErbB Receptors